Dapagliflozin and empagliflozin showed significant benefit, while canagliflozin did not.<h4>Conclusion</h4>Use of SGLT2 inhibitors is significantly associated with lower dementia risk compared to DPP-4 inhibitors in patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.